New strategies for the design and development of protein antimicrobials based on phage products

Nowadays, antibiotic resistance is one of the most urgent global health issues to be tackled. Among the infective bacteria, Gram-negative ones are the main causative agents of nosocomial infections, causing an important death burden, partly due to anti-microbial resistance. Currently, phage therapy...

Descripción completa

Detalles Bibliográficos
Autor: Vázquez Fernández, Roberto
Tipo de recurso: tesis doctoral
Fecha de publicación:2021
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/5646
Acceso en línea:https://hdl.handle.net/20.500.14352/5646
Access Level:acceso abierto
Palabra clave:577.18.08(043.2)
Antiobitcs
Antibióticos
Medicamentos
id ES_b94917c3fd4e73e39c950e15ae32ce9d
oai_identifier_str oai:docta.ucm.es:20.500.14352/5646
network_acronym_str ES
network_name_str España
repository_id_str
spelling New strategies for the design and development of protein antimicrobials based on phage productsNuevas estrategias para el diseño y desarrollo de antimicrobianos proteicos basados en productos fágicosVázquez Fernández, Roberto577.18.08(043.2)AntiobitcsAntibióticosMedicamentosNowadays, antibiotic resistance is one of the most urgent global health issues to be tackled. Among the infective bacteria, Gram-negative ones are the main causative agents of nosocomial infections, causing an important death burden, partly due to anti-microbial resistance. Currently, phage therapy research is experiencing a renaissance as a viable alternative or complement to common antimicrobial chemotherapy. Not only complete virion particles but also phage-derived products have a series of advantages over antibiotics. In particular, phage (endo)lysins are the phage-encoded proteins re-sponsible for bacterial host lysis and subsequent death due to their cell wall lytic activity. Lysins are being repurposed to be exogenously applied, in a purified form, against bac-teria, functioning as lytic antimicrobials, and thus are also called ‘enzybiotics’. Among the many advantages of enzybiotics, we may cite their lower chance to provoke resistance in the target bacteria and their versatility to be screened and engineered using bioinfor-matic and biotechnological tools...Universidad Complutense de MadridGarcía Fernández, PedroUniversidad Complutense de Madrid20212021-08-3120212021-08-31doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttps://hdl.handle.net/20.500.14352/5646reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/56462026-06-02T12:44:21Z
dc.title.none.fl_str_mv New strategies for the design and development of protein antimicrobials based on phage products
Nuevas estrategias para el diseño y desarrollo de antimicrobianos proteicos basados en productos fágicos
title New strategies for the design and development of protein antimicrobials based on phage products
spellingShingle New strategies for the design and development of protein antimicrobials based on phage products
Vázquez Fernández, Roberto
577.18.08(043.2)
Antiobitcs
Antibióticos
Medicamentos
title_short New strategies for the design and development of protein antimicrobials based on phage products
title_full New strategies for the design and development of protein antimicrobials based on phage products
title_fullStr New strategies for the design and development of protein antimicrobials based on phage products
title_full_unstemmed New strategies for the design and development of protein antimicrobials based on phage products
title_sort New strategies for the design and development of protein antimicrobials based on phage products
dc.creator.none.fl_str_mv Vázquez Fernández, Roberto
author Vázquez Fernández, Roberto
author_facet Vázquez Fernández, Roberto
author_role author
dc.contributor.none.fl_str_mv García Fernández, Pedro
Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 577.18.08(043.2)
Antiobitcs
Antibióticos
Medicamentos
topic 577.18.08(043.2)
Antiobitcs
Antibióticos
Medicamentos
description Nowadays, antibiotic resistance is one of the most urgent global health issues to be tackled. Among the infective bacteria, Gram-negative ones are the main causative agents of nosocomial infections, causing an important death burden, partly due to anti-microbial resistance. Currently, phage therapy research is experiencing a renaissance as a viable alternative or complement to common antimicrobial chemotherapy. Not only complete virion particles but also phage-derived products have a series of advantages over antibiotics. In particular, phage (endo)lysins are the phage-encoded proteins re-sponsible for bacterial host lysis and subsequent death due to their cell wall lytic activity. Lysins are being repurposed to be exogenously applied, in a purified form, against bac-teria, functioning as lytic antimicrobials, and thus are also called ‘enzybiotics’. Among the many advantages of enzybiotics, we may cite their lower chance to provoke resistance in the target bacteria and their versatility to be screened and engineered using bioinfor-matic and biotechnological tools...
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-08-31
2021
2021-08-31
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/5646
url https://hdl.handle.net/20.500.14352/5646
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Complutense de Madrid
publisher.none.fl_str_mv Universidad Complutense de Madrid
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417759321882624
score 15,300719

Similares en LA Referencia